{"id":"ibi343-sintilimab-oxaliplatin-s-1","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sintilimab is a monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), preventing its interaction with programmed death-1 (PD-1) on T cells, thereby enhancing T cell-mediated immune response against cancer cells.","oneSentence":"Programmed death-ligand 1 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:50.429Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07483567","phase":"PHASE2","title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-30","conditions":"CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07025889","phase":"PHASE1, PHASE2","title":"IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-02","conditions":"Gastric Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"IBI343,sintilimab,oxaliplatin,S-1","genericName":"IBI343,sintilimab,oxaliplatin,S-1","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Programmed death-ligand 1 inhibitor Used for Non-small cell lung cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}